NRG Therapeutics
NRG Therapeutics is a neuroscience-focused drug discovery company dedicated to developing disease-modifying treatments for neurodegenerative disorders such as Parkinson’s and ALS. The company leverages breakthrough science in mitochondrial biology to identify new therapeutic targets, focusing on inhibitors of the mitochondrial permeability transition pore (mPTP) that are orally bioavailable and brain-penetrant. Their mission is to slow or halt disease progression and bring hope to patients worldwide.
Industries
Nr. of Employees
small (1-50)
NRG Therapeutics
Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Herts, SG1 2FX, UK
Patents
Products
Pipeline of brain-penetrant small-molecule mPTP inhibitors (preclinical)
Structurally differentiated small-molecule series designed to inhibit the mitochondrial permeability transition pore with oral bioavailability and CNS penetration; developed for potential disease-modifying treatment of Parkinson's disease and ALS/MND.
Development candidate: first-in-class brain-penetrant mPTP inhibitor (development candidate)
A nominated preclinical development candidate designed to prevent mitochondrial dysfunction via inhibition of a protein essential for mPTP opening; intended for advancement into first-in-human clinical studies.
Pipeline of brain-penetrant small-molecule mPTP inhibitors (preclinical)
Structurally differentiated small-molecule series designed to inhibit the mitochondrial permeability transition pore with oral bioavailability and CNS penetration; developed for potential disease-modifying treatment of Parkinson's disease and ALS/MND.
Development candidate: first-in-class brain-penetrant mPTP inhibitor (development candidate)
A nominated preclinical development candidate designed to prevent mitochondrial dysfunction via inhibition of a protein essential for mPTP opening; intended for advancement into first-in-human clinical studies.
Services
Execution of integrated lead optimisation programs through external discovery services partners to improve pharmaceutical properties and progress candidates toward preclinical nomination.
Sponsorship and management of collaborative research with academic institutes to validate targets, develop biomarkers and perform translational studies.
Execution of integrated lead optimisation programs through external discovery services partners to improve pharmaceutical properties and progress candidates toward preclinical nomination.
Sponsorship and management of collaborative research with academic institutes to validate targets, develop biomarkers and perform translational studies.
Expertise Areas
- Mitochondrial-targeted drug discovery
- Neurodegenerative disease therapeutics (Parkinson's, ALS/MND)
- Small-molecule medicinal chemistry and lead optimisation
- Preclinical candidate selection and IND-enabling development
Key Technologies
- Phenotypic screening in isolated mitochondria
- Chemoproteomics for target ID
- Small-molecule medicinal chemistry
- Lead optimisation and ADME/PK profiling
News & Updates
NRG5051 is a first-in-class inhibitor of the mitochondrial permeability transition pore (mPTP) designed to penetrate the brain when taken orally. It has shown neuroprotective effects in preclinical models of Parkinson’s and ALS, and the company has secured a $5 million grant from The Michael J. Fox Foundation to support its development into clinical trials.
NRG received a grant from Target ALS to support its discovery program for small molecule inhibitors of the mPTP as treatments for ALS. The project aims to validate a new mitochondrial drug target and develop therapies that can prevent mitochondrial dysfunction and neurodegeneration in ALS models.
Vad Lazari Ph.D. joins NRG as VP of Biology, responsible for leading biological research to support the development of small molecule inhibitors of the mPTP for Parkinson’s and ALS.
NRG has formed an international scientific advisory board comprising experts in neuroscience, drug discovery, and clinical development to support its R&D programs targeting neurodegenerative diseases.
NRG received a second grant from MJFF to validate a novel mitochondrial drug target for Parkinson’s and to develop NRG5051 into clinical trials, with anticipated first-in-human studies by 2025.
PwC highlights NRG Therapeutics as a leading biotech in the life sciences sector.
NRG5051 is a first-in-class inhibitor of the mitochondrial permeability transition pore (mPTP) designed to penetrate the brain when taken orally. It has shown neuroprotective effects in preclinical models of Parkinson’s and ALS, and the company has secured a $5 million grant from The Michael J. Fox Foundation to support its development into clinical trials.
NRG received a grant from Target ALS to support its discovery program for small molecule inhibitors of the mPTP as treatments for ALS. The project aims to validate a new mitochondrial drug target and develop therapies that can prevent mitochondrial dysfunction and neurodegeneration in ALS models.
Vad Lazari Ph.D. joins NRG as VP of Biology, responsible for leading biological research to support the development of small molecule inhibitors of the mPTP for Parkinson’s and ALS.
NRG has formed an international scientific advisory board comprising experts in neuroscience, drug discovery, and clinical development to support its R&D programs targeting neurodegenerative diseases.
NRG received a second grant from MJFF to validate a novel mitochondrial drug target for Parkinson’s and to develop NRG5051 into clinical trials, with anticipated first-in-human studies by 2025.
PwC highlights NRG Therapeutics as a leading biotech in the life sciences sector.